Ganglioglioma with MAP2K1 Mutation and CDKN2A/B Homozygous Deletion: A Case Report.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Zhao C;Zhao C; Li C; Li C; Ge JJ; Ge JJ; Zhang JP; Zhang JP
  • Source:
    British journal of hospital medicine (London, England : 2005) [Br J Hosp Med (Lond)] 2024 Oct 30; Vol. 85 (10), pp. 1-10. Date of Electronic Publication: 2024 Oct 14.
  • Publication Type:
    Case Reports; Journal Article
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: MA Healthcare Country of Publication: England NLM ID: 101257109 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1750-8460 (Print) Linking ISSN: 17508460 NLM ISO Abbreviation: Br J Hosp Med (Lond) Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : MA Healthcare, c2005-
    • Subject Terms:
      Ganglioglioma*/genetics ; Ganglioglioma*/pathology ; Brain Neoplasms*/genetics ; Brain Neoplasms*/pathology ; Cyclin-Dependent Kinase Inhibitor p16*/genetics ; MAP Kinase Kinase 1*/genetics; Humans ; Child, Preschool ; Male ; Mutation ; Cyclin-Dependent Kinase Inhibitor p15/genetics ; Temozolomide/therapeutic use ; Homozygote ; Irinotecan/therapeutic use
    • Abstract:
      Aims/Background Gangliogliomas are grade 1 glioneuronal tumors occurring predominantly in the temporal lobe, as per the World Health Organization (WHO) classification. Gangliogliomas often harbor BRAF (v-Raf murine sarcoma viral oncogene homolog B1) p.V600E hotspot mutation or other alterations leading to activation of RAS/RAF/MAPK (rat sarcoma virus oncogene/rapidly accelerated fibrosarcoma/mitogen-activated protein kinase) signaling pathway, which is the driver factor of this tumor. This study aims to investigate a case of ganglioglioma patient with distinctive molecular features, and to present the clinical and pathological characteristics as well as the treatment employed for this individual. Case Presentation We reported a primary ganglioglioma harboring MAP2K1 (mitogen-activated protein kinase kinase 1) mutation and CDKN2A/B (cyclin-dependent kinase inhibitor 2A/2B) homozygous deletion in a 4-year-old patient. The patient experienced tumor recurrence 12 months after gross total resection of the tumor. Subsequently, salvage chemotherapy with a combination of temozolomide and irinotecan was administered, resulting in effective control of the tumor. Conclusion To our knowledge, this is the first reported case of ganglioglioma with anaplastic features harboring MAP2K1 mutation and homozygous deletion of CDKN2A/B . These findings may shed light on the genetic features of ganglioglioma and offers insights into potential therapeutic approaches for this rare neoplasm.
    • Contributed Indexing:
      Keywords: CDKN2A/B homozygous deletion; MAP2K1 mutation; anaplastic; chemotherapy; ganglioglioma
    • Accession Number:
      0 (Cyclin-Dependent Kinase Inhibitor p16)
      EC 2.7.12.2 (MAP Kinase Kinase 1)
      EC 2.7.12.2 (MAP2K1 protein, human)
      0 (CDKN2A protein, human)
      0 (Cyclin-Dependent Kinase Inhibitor p15)
      YF1K15M17Y (Temozolomide)
      0 (CDKN2B protein, human)
      7673326042 (Irinotecan)
    • Publication Date:
      Date Created: 20241030 Date Completed: 20241030 Latest Revision: 20241030
    • Publication Date:
      20241031
    • Accession Number:
      10.12968/hmed.2024.0379
    • Accession Number:
      39475028